"Pharmaceutical Speed Reader" Sansheng Guoke Co., Inc. IPO ipo of Gilead's $1.25 billion deal.

July 22, 2020 / Medical Information List: Sansheng Guojian today science and technology board IPO listing; the latest village health room standards out; for type 2 diabetes sotagliflozin 4 Phase III clinical all reached the main end point; Kangfang biological CD47 monotonic declaration in China clinical; Jiahe bioPD-1 monoto-drug submission application for treatment of peripheral T-cell lymphoma ... Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Briefing Update Village Health Room Standards are out. Village medical qualifications need to meet this requirement Recently, Shandong Provincial Health And Welfare Commission issued "on the issuance of "Shandong Province primary health care service capacity improvement action three-year plan" related to the medical and health institutions service capacity standards," published the "Shandong Province Village Health Room provincial demonstration standards", which mentioned: the minimum qualification of village doctors for the village general, infusion rate of 25%, antibacterial drug prescription ratio of 20%, village health room staff wages are not lower than the average of the same conditions.
(Shandong Province Health And Health Commission) Part 2 production and observation of Sansheng Guojian today Science and Innovation Board IPO listing Of Sansheng Guojian officially listed on the science and technology board listing, the number of shares issued does not exceed 6162.1142 million shares, the issue price is 28.18 yuan / share, the corresponding price-earnings ratio of 75.73 times, by Taihua United Securities as the sponsor body, CITIC Securities as the joint main underwriter.
(Pharma Rubik's Cube) Gilead struck a $1.25 billion deal to develop oncology immunotherapy on the 21st, Gilead announced that it will invest $300 million in Tizona Therapeutics, acquiring a 49.9 percent stake in the latter, while owning an exclusive option to acquire the remaining 50.1 percent of the latter, with future exercise fees and potential mileage of $1.25 billion.
Gilead funded Tizona to develop differentiated first in class oncology immunotherapy.
(Pharmaceutical Rubik's Cube) Part 3 Drug Information for Type 2 Diabetes Sotagliflozin 4 Phase III Clinical Endpoint Lexicon Corporation has published the top line data for SGLT 1/2 inhibitor sotagflozin for 4 Phase III clinical studies of type 2 diabetes (T2D): 4 studies (SOTA-MONO, SOTA-SOTA, SOTA-GLIM, S-INS) all reached the primary end point of the patient.)
(Sina Pharmaceutical News) Abbvie upadacitinib single drug treatment of teraphritis Phase 2 Phase III clinical success 21, AbbVie announced Rinvoq (upadacitinib, 15mg and 30mg, once a day) single drug treatment of moderate-to-retinal dermatitis phase 2 phase 3 clinical trial Ofmeasure Up 2 reached the main end and all secondary endpoints.
compared to placebo, upadacitinib showed significant improvement in skin removal and reduced itching at week 16.
(Sina Pharmaceutical News) FDA approved Ivetinib to launch the new crown phase II clinical recently, the U.S. FDA officially approved the launch of Ivetinib for COVID-19 virus infection caused by moderate to severe pneumonia patients a double-blind, with standard treatment randomized control effectiveness and safety of Phase II clinical study.
this means that the lung cancer drug Iveitinib has begun the search against the new coronavirus.
(E drug manager) Yanyuan Pharmaceutical ROS1/NTRK inhibitor China Phase 2 clinical admission group of patients Yanyuan Medicine 21 announced that its next generation OF ROS1/NTRK inhibitors for the local progression of the ROS1 fusion gene or systemic metastasis of advanced non-small cell lung cancer phase 2 clinical trial into the first class of Chinese subjects.
this one-arm, open clinical study evaluating the effectiveness and safety of patients with advanced non-small cell lung cancer with AB-106 treatment or systemic metastasis, with Professor Zhou Caixuan of Shanghai Lung Hospital as the national leading researcher.
(Pharmaceutical Mission) Kangfang biological CD47 monotoresist in China declared clinical 21, CDE publicity, Kangfang Biological's class 1 new drug AK117 injection declared clinical trial, and obtained CDE acceptance.
this is a monoclonal antibody targeting CD47, which has previously been approved by IND in the United States and completed its first patient intake and administration in Australia in May this year.
(CDE) Astellas leukemia new drug Giritinib was included in the proposed priority review of the CDE website update, Astellas Fuma acid Giritinib tablets were included in the proposed priority review list on July 21, on the grounds that "drugs that meet the conditions approved."
, a next-generation FLT3 tyrosine kinase inhibitor, has been approved in the United States, Japan and Europe and other countries and regions for the treatment of recurrent or refractive FLT3 mutation acute myeloid leukemia adult patients.
(CDE) Hengrui Pharmaceutical injection SHR-A1811 clinical trial approval Hengrui Pharmaceuticals announced that the company and subsidiaries Suzhou Shengdia Bio, Shanghai Hengrui Pharmaceuticals recently received the Approval of Drug Clinical Trials issued by the State Drug Administration, agreed to carry out injection SHR-A1811 for THE treatment of HER2 expression or mutation of advanced solid tumor clinical trials.
(Hengrui Pharmaceutical Announcement) Jiahe BioPD-1 Monotavirus Submitted New Drug Listing Application Treatment Peripheral T-Cell Lymphoma Jia and Bio 21 announced that its PD-1 antibody Geptanolima injection (geptanolimab, research and development code GB226) of the new drug market application (NDA) has been accepted by the National Drug Administration for the treatment of peripheral T-cell lymphoma (PTCL).
, Genomono, which can be used to treat a variety of late-stage solid tumors, restores the immune system's ability to recognize and kill cancer cells by selectively blocking the dual ligand.
(Pharmaceutical Mission) Qingping Pharmaceuticals sodium valproate tablets through consistency evaluation recently, the official website of the State Drug Administration shows that Qingping Pharmaceuticals sodium valproate tablets through consistency evaluation, for the first in China.
sodium valproate is a nitrogen-free broad-spectrum anti-epileptic drug, can competitively inhibit Y-aminobutyric acid transaminase, improve the concentration of Y-aminobutyric acid to achieve anticonvulsive effect, all types of small seizures, muscle-array epilepsy, limited seizures, large seizures and mixed epilepsy are effective, clinically more used in other anti-epileptic drugs are ineffective with various epilepsy.
(NSA) for the treatment of lupus nephritis voclosporin was fda-prioritized aurinia announced that the FDA has accepted the company's new drug application for voclosporin (NDA) as a potential treatment for lupus nephritis.
FDA has granted the NDA priority review status and is expected to respond by January 22, 2021. qutenza,
(Drug Mingcon) Qutenza has been approved by the U.S. FDA for the treatment of diabetes-related neuropathy, Gr?nenthal announced that its subsidiary, Averitas Pharma Qutenza (capsaicin) 8% of the adhesive, has been approved by the U.S. FDA for the treatment of adult foot diabetes peripheral neuropathy (DPN) related neuropathy.
Qutenza is a local, non-systemic, non-opioid pain treatment drug delivered as a patch, and is the first and only treatment that delivers prescription-specific capsaicin directly to the skin.
(immediate medicine) Haizheng Pharmaceutical hydrochloric acid Moxisasin RAW pharmaceutical obtained CEP certificate Haizheng Pharmaceuticals issued a notice that recently, its wholly-owned subsidiary Haizheng Nantong Company received EDQM issued the European Pharmacopoeia certification certificate of hydrochloric acid Moxisarsin API.
at present at home and abroad hydrochloric acid Moxishaxing raw materials main production and sales manufacturers have BAYER PHARMA, KRKA, Sichuan for pharmaceutical, Nanjing Youke Pharmaceuticals and so on.
(Haizheng PharmaceuticalS) Scientists found that the new gene editing tool is half the size of CRISPR-Cas9, and researchers at the Institute of Innovative Genomics at the University of California, Berkeley, usa, have discovered a new gene editing tool, Cas, the smallest CRISPR-Cas system, consisting of 1 to 70 KD Cas-spprotein and a CRISPR array, encoded only in the genome of giant bacteria, and is half of CRISPR-Cas 9.
(Biodiscovery)